These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 36555792)

  • 41. Experimental models of dermal fibrosis and systemic sclerosis.
    Avouac J; Elhai M; Allanore Y
    Joint Bone Spine; 2013 Jan; 80(1):23-8. PubMed ID: 22841579
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis.
    Kondo M; Suzuki T; Kawano Y; Kojima S; Miyashiro M; Matsumoto A; Kania G; Błyszczuk P; Ross RL; Mulipa P; Del Galdo F; Zhang Y; Distler JHW
    Arthritis Res Ther; 2022 Sep; 24(1):210. PubMed ID: 36050717
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Microbiome dysbiosis is associated with disease duration and increased inflammatory gene expression in systemic sclerosis skin.
    Johnson ME; Franks JM; Cai G; Mehta BK; Wood TA; Archambault K; Pioli PA; Simms RW; Orzechowski N; Arron S; Whitfield ML
    Arthritis Res Ther; 2019 Feb; 21(1):49. PubMed ID: 30728065
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Involvement of the myeloid cell compartment in fibrogenesis and systemic sclerosis.
    Kania G; Rudnik M; Distler O
    Nat Rev Rheumatol; 2019 May; 15(5):288-302. PubMed ID: 30953037
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Insights into the knowledge of complex diseases: Environmental infectious/toxic agents as potential etiopathogenetic factors of systemic sclerosis.
    Ferri C; Arcangeletti MC; Caselli E; Zakrzewska K; Maccari C; Calderaro A; D'Accolti M; Soffritti I; Arvia R; Sighinolfi G; Artoni E; Giuggioli D
    J Autoimmun; 2021 Nov; 124():102727. PubMed ID: 34601207
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pathogenesis of vasculopathy in systemic sclerosis and its contribution to fibrosis.
    Kawaguchi Y; Kuwana M
    Curr Opin Rheumatol; 2023 Nov; 35(6):309-316. PubMed ID: 37490353
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Engineering Advanced In Vitro Models of Systemic Sclerosis for Drug Discovery and Development.
    De Pieri A; Korman BD; Jüngel A; Wuertz-Kozak K
    Adv Biol (Weinh); 2021 Apr; 5(4):e2000168. PubMed ID: 33852183
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Critical Appraisal of the Utility and Limitations of Animal Models of Scleroderma.
    Tsujino K; Sheppard D
    Curr Rheumatol Rep; 2016 Jan; 18(1):4. PubMed ID: 26711695
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low RUNX3 expression alters dendritic cell function in patients with systemic sclerosis and contributes to enhanced fibrosis.
    Affandi AJ; Carvalheiro T; Ottria A; Broen JC; Bossini-Castillo L; Tieland RG; Bon LV; Chouri E; Rossato M; Mertens JS; Garcia S; Pandit A; de Kroon LM; Christmann RB; Martin J; van Roon JA; Radstake TR; Marut W
    Ann Rheum Dis; 2019 Sep; 78(9):1249-1259. PubMed ID: 31126957
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Investigational drugs for the treatment of scleroderma: what's new?
    Colic J; Campochiaro C; Hughes M; Matucci Cerinic M; Dagna L
    Expert Opin Investig Drugs; 2023; 32(7):601-614. PubMed ID: 37526079
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [B cell abnormalities and therapeutic strategies in systemic sclerosis].
    Yoshizaki A
    Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):197-206. PubMed ID: 27320935
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MicroRNAs: their involvement in fibrosis pathogenesis and use as diagnostic biomarkers in scleroderma.
    Zhu H; Luo H; Zuo X
    Exp Mol Med; 2013 Sep; 45(9):e41. PubMed ID: 24052166
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Animal models of scleroderma: lessons from transgenic and knockout mice.
    Derrett-Smith EC; Denton CP; Sonnylal S
    Curr Opin Rheumatol; 2009 Nov; 21(6):630-5. PubMed ID: 19730378
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
    Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
    Front Immunol; 2020; 11():1990. PubMed ID: 33013852
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hydrogen Sulfide: A Therapeutic Option in Systemic Sclerosis.
    Abdulle AE; van Goor H; Mulder DJ
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30572591
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis.
    Wu M; Skaug B; Bi X; Mills T; Salazar G; Zhou X; Reveille J; Agarwal SK; Blackburn MR; Mayes MD; Assassi S
    Ann Rheum Dis; 2019 Nov; 78(11):1583-1591. PubMed ID: 31439591
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An update on biomarker discovery and use in systemic sclerosis.
    Matsushita T; Takehara K
    Expert Rev Mol Diagn; 2017 Sep; 17(9):823-833. PubMed ID: 28730919
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Involvement of Disabled-2 on skin fibrosis in systemic sclerosis.
    Mei X; Zhao H; Huang Y; Tang Y; Shi X; Pu W; Jiang S; Ma Y; Zhang Y; Bai L; Tu W; Zhao Y; Jin L; Wu W; Wang J; Liu Q
    J Dermatol Sci; 2020 Jul; 99(1):44-52. PubMed ID: 32571632
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recent advances in animal models of systemic sclerosis.
    Asano Y
    J Dermatol; 2016 Jan; 43(1):19-28. PubMed ID: 26782003
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of metabolism in the pathogenesis of systemic sclerosis.
    Zhu H; Chen W; Liu D; Luo H
    Metabolism; 2019 Apr; 93():44-51. PubMed ID: 30586574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.